Option Chain

Harrow Inc

HROWNASDAQ · USD

28.85USD+0.31 (+1.07%)

325

Harrow Inc (HROW) Option Chain

Harrow Inc trades at $28.85, up 1.07%, with an IV Rank of 87.70%. This is high versus the past year, and the company carries a market cap of $1,070M in the Drug Manufacturers - Specialty & Generic industry. On the Nov 20, 2026 chain, the at the money $29.00 strike shows calls at $0.40 / $4.20 and puts at $0.95 / $4.90, both carrying about $2.54 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $30.00 calls, at 3 contracts, and the $35.00 puts, at 3, as of Nov 3, 2026.

Tracking the HROW option chain helps you see every strike and expiry on Harrow Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of HROW options activity at a glance. Use our scanner to monitor the HROW option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For HROW stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where HROW options are being actively traded, and where they are not.

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
42.38	0	0	1.37	1.85	1.25	5.20	27.00	-5.40	0.05	4.00	0.00	2.03	0	3	57.62
49.70	1	0	1.92	0.85	0.65	4.90	28.00	-1.89	1.20	2.80	0.00	2.00	0	55	50.30
56.77	0	0	2.30	0.00	0.40	4.20	29.00	+1.61	0.95	4.90	0.15	2.78	0	11	43.23
63.40	93	3	1.95	0.00	0.90	3.00	30.00	+5.12	1.65	4.90	1.15	2.13	0	110	36.60
69.45	56	0	1.70	0.00	0.10	3.30	31.00	+8.62	1.95	6.10	2.15	1.88	0	4	30.55

As of Nov 3, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
IV Rank87.70% High
Market cap (M$)1,070
52 weeks high-47.97%
52 weeks low5.86%
Analyst recommendationStrong Buy
1.00
Target price$63.78
125.34% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-11-09
P/E—
Future P/E13.55
EPS (ttm)-1.00
EPS growth next 5 years—

As of Nov 3, 2026

Browse all Option Chain tickers